1.
Descamps-Latscha B, Jungers P: New molecular aspects of chronic uraemia and dialysis-related immunocompetent cell activation. Nephrol Dial Transplant 1996;11(suppl 2):S121–S124.
2.
London WT, Difiglia M, Sutnick AI, Blumberg BS: An epidemic of hepatitis in a chronic hemodialysis unit. N Engl J Med 1969;281:571–578.
3.
Rautenberg P, Proppe D, Schutte A, Ullman U: Influenza subtype-specific immunoglobulin A and G responses after booster versus one double-dose vaccination in hemodialysis patients. Eur J Clin Microbiol Infect Dis 1989;8:897–900.
4.
Girndt M, Pietsch M, Kohler H: Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure. Am J Kidney Dis 1995;26:454–460.
5.
Kreft B, Klouche M, Kreft R, Kirchner H, Sack L: Low efficiency of active immunization against diphteria in chronic hemodialysis patients. Kidney Int 1997;52:212–216.
6.
Friedman EA, Beyer MM, Hirsch SR, Schiffman G: Intact antibody response to pneumococcal capsular polysaccharides in uremia and diabetes. JAMA 1980;244:2310–2311.
7.
Chatenoud L, Dugas B, Beaurain G, et al: Presence of preactivated T cells in hemodialyzed patients: Their possible role in altered immunity. Proc Natl Acad Sci USA 1986;83:7457–7461.
8.
Descamps-Latscha B, Chatenoud L: T cells and B cells in chronic renal failure. Semin Nephrol 1996;16:138–191.
9.
Descamps-Latscha B: The immune system in end-stage renal disease. Curr Opin Nephrol Hypertens 1993;2:883–891.
10.
Pillion G, Chiesa M, Maisin A, Schlegel N, Noirat C: Immunogenicity of hepatitis B vaccine (HEVAC B) in children with advanced renal failure. Pediatr Nephrol 1990;4:627–629.
11.
Mege JL, Capo C, Purgus R, Olmer M: Monocyte production of transforming growth factor β in long term hemodialysis: Modulation by hemodialysis membranes. Am J Kidney Dis 1996;28:395–399.
12.
Mosmann TR, Cherrwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348–2357.
13.
Parronchi PD, Mancia MP, Piccini MP, Biswas P, Simonelli C, Maggi E, Ricci M, Anari AA, Romagnini S: Allergen- and bacterial antigen-specific T-cell clones established from atopic donors show a different profile of cytokine production. Proc Natl Acad USA 1991;88:4538–4542.
14.
Powrie F, Coffman RL: Cytokine regulation of T-cell function: Potential for therapeutic intervention. Immunol Today 1993;14:270–274.
15.
Mosmann TR, Coffman RL: Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145–173.
16.
Rook GAW, Hernandez-Pando R, Lightman SL: Hormones, peripherally activated prohormones and regulation of the Th1/Th2 balance. Immunol Today 1994;15:301–303.
17.
Beaurain G, Naret C, Marcon L, et al: In vivo T cell preactivation in chronic uremic hemodialyzed and non-hemodialyzed patients. Kidney Int 1989;36:636–644.
18.
Chatenoud L, Herbelin A, Beaurain G, Descamps-Latscha B: Immune deficiency of the uremic patients. Adv Nephrol Necker Hosp 1990;19:259–274.
19.
Hsfeb CS, Macatonia SE, Tripp CS, Wolf SF, O’Garra A, Murphy KM: Development of Th1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993;260:547–549.
20.
Sester U, Sester M, Hauk M, Kaul H, Kohler H, Girndt M: T-cell activation follows Th1 rather than Th2 pattern in hemodialysis patients. Nephrol Dial Transplant 2000;15:1217–1223.
21.
Greenfield EA, Nguyen KA, Kuchroo VK: CD28/B7 costimulation: A review. Crit Rev Immunol 1998;18:389–418.
22.
Williams TM, Moolten DM, Makni H, Kim HW, Kant JA, Kamoun M: CD28-stimulated IL-2 gene expression in Jurkat T cells occurs in part transcriptionally and is cyclosporine-A sensitive. J Immunol 1992;148:2609–2616.
23.
Daichou Y, Kurashige S, Hashimoto S, Suzuki S: Characteristic cytokine products of Th1 and Th2 cells in hemodialysis patients. Nephron 1999;83:237–245.
24.
Donati D, Degiannis D, Homer L, Gastaldi L, Raskova J, Raska K Jr: Immune deficiency in uremia: Interleukin-2 production and responsiveness and interleukin-2 receptor expression and release. Nephron 1991;58:268–275.
25.
Lortan JE, Kiepicla P, Coovadia HM, Seedat YK: Suppressor cells assayed by numerical and functional tests in chronic renal failure. Kidney Int 1982;22:192–197.
26.
Nanishi F, Inenaga T, et al: Immune alterations in hemodialyzed patients. Effect of blood transfusion on T-lymphocyte subpopulations in hemodialyzed patients. J Clin Lab Immunol 1986;19:167–174.
27.
Shabtai M, Avigad I, Schachter P, Czerniak A, Judich A, Ayalon A: Analysis of peripheral blood lymphocyte cell surface density of functional and activation associated markers in young and old hemodialysis patients. J Urol 1993;150:1369–1374.
28.
Chida J, Sakurai S, Yoshiyama N: The effect of hemodialysis on lymphocyte subsets during dialysis. Clin Nephrol 1986;25:159–164.
29.
Kurz P, Koler H, Meyer SC, Hutteroh T: Impaired cellular immune response in chronic renal failure. Kidney Int 1986;29:1209–1214.
30.
Waltzer WC, Bachvaroff RJ, Raisbeck A, Egelandsdal B, Pullis C, Shen E, Rapaport TF: Immunological monitoring in patients with end-stage renal disease. J Clin Immunol 1984;4:364–369.
31.
Bendeer BC, Curtis JL, Nagel JE, Chrest FJ, Kraus ES, Briefel GR, Adler WH: Analsis of immune status of hemodialyzed adults: Association with prior transfusion. Kidney Int 1984;26:435–443.
32.
Tvede N, Kappel M, Halkiar-Kristenson H, Galbo H, Pedersen BK: The effect of light, moderate and severe bicycle exercise on lymphocyte subsets, natural and lymphokine activated killer cells, lymphocyte proliferative response and interleukin 2 production. Int J Sports Med 1993;14:275–282.
33.
Dinarello CA: Cytokines: Agents provocateurs in hemodialysis? Kidney Int 1992;41:683–694.
34.
Chopra RJ, Powers DR, Kendig NE, Adler WH, Nagel JE: Soluble interleukin 2 receptors released from mitogen-stimulated human peripheral blood lymphocytes bind interleukin 2 and inhibit IL-2 dependent cell proliferation. Immunol Invest 1989;18:961–973.
35.
Clovin RB, Fuller TC, MacKeen L: Plasma interleukin-2 receptor levels in renal allograft recipients. Clin Immunol Immunopathol 1987;43:273–276.
36.
Walz G, Kunzendorf U, Josimovic-Alasevic O, Preushoff L, Schwarz A, Keller F, Asmus G, Offerman G, Diamantstein T, Distler A: Soluble interleukin 2 receptor and tissue polypeptide antigen serum concentration in end-stage renal failure. Nephron 1990;56:157–161.
37.
Rubin LA, Nelson DL: The soluble interleukin 2 receptor: Biology, function and clinical application. Ann Intern Med 1990;113:619–627.
38.
Rubin LA, Jay G, Nelson DL: The released interleukin 2 receptor binds interleukin 2 efficiently. J Immunol 1986;137:3841–3844.
39.
Morita Y, Yamamura M, Kashihara N, Makino H: Increased production of interleukin-10 and inflammatory cytokines in blood monocytes of hemodialysis patients. Mol Pathol Pharmacol 1997;98:19–33.
40.
Hayakawa M, Hatano T, Sunabe T, Higa I, Osawa A: Cytokine production and cytotoxicity of lymphocytes in patients on maintenance short- or long-term hemodialysis. Nephrol Dial Transplant 1994;9:655–661.
41.
Melchers IKF, Eichmann K: Quantitative studies on T cell diversity: Limiting dilution analysis of precursor cells for T helper cells reactive to xenogenic erythrocytes. J Exp Med 1982;156:1587–1603.
42.
Donnely RP, Freeman SL, Hayes MP: Inhibition of IL-10 expression by IFN-γ upregulates transcription of TNF-α in human monocytes. J Immunol 1995;155:1420–1427.
43.
Fiorentino DF, Bond MW, Mosmann TR: Two types of mouse T helper cell. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989;170:2081–2095.
44.
Daniel V, Trautmann Y, Konrad M, Nayir A, Scharer K: T-lymphocyte populations, cytokines and other growth factors in serum and urine of children with idiopathic nephritic syndrome. Clin Nephrol 1997;47:289–297.
45.
Tripp CS, Wolf SF, Unanue ER: Interleukin 12 and tumor necrosis factor are costimulators of interferon γ production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci USA 1993;90:3725–3729.
46.
Okamura H, Tsutsui H, et al: Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 1995;378:88–91.
47.
Eszter N, Buhlmann JE, Henics T, Waugh M, Rigby WFC: Selective modulation of IFN-γ mRNA stability by IL-12/NKSF. Cell Immunol 1994;159:140–151.
48.
Nockher WA, Soberberich JE: Expanded CD14+ CD16+ monocyte subpopulation in patients with acute and chronic infections undergoing hemodialysis. Infect Immun 1998;66:2782–2790.
49.
Girndt M, Kohler M, Schiedheim WE, Schlaak IF, et al: Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune deficit in chronic hemodialysis patients. Kidney Int 1995;47:559–565.
50.
Girndt M, Lengler S, Kaul H, Sester U, Sester M, Kohler H: Prospective crossover trial of the influence of vitamin E coated dialyzer membranes on T-cell activation and cytokine induction. Am J Kidney Dis 2000;35/1:95–104.
51.
Galli F, Rovidati S, Chiarantini L, Campus G, Canestrari F, Buoncristiani U: Bioreactivity and biocompatibility of a vitamin E-modified multilayer hemodialysis filter. Kidney Int 1998;54:580–589.
52.
Cristol JP, Canaud B, Rabedandratana H, Gailard I, Serre A, Mion C: Enhancement of reactive oxygen species production and cell surface markers expression due to hemodialys. Nephrol Dial Transplant 1994;9:389–394.
53.
Rice-Evans CA, Diplock AT: Current status of antioxidant therapy. Tree Radic Biol Med 1993;15:77–96.
54.
Betz M, Haensch GM, Rauterberg EW, Bommer J, Ritz E: Cuprammonium membranes stimulate interleukin-1 release and arachidonic acid metabolism monocytes in the absence of complement. Kidney Int 1988;34:67–73.
55.
Schindler R, Lennemann G, Shaldon S, Koch KM, Dinarello CA: Transcription, not synthesis of interleukin-1 and tumor necrosis factor by complement. Kidney Int 1990;37:85–93.
56.
Hansch GM, Seitz M, Betz M: Effect of late complement components C5b-9 on human monocytes: Release of prostanoids, oxygen radicals and a factor inducing cell proliferation. Int Arch Allergy Appl Immunol 1987;82:317–320.
57.
Pertosa G, Gesualdo L, Bottalico D, Schena FP: Endotoxins modulate chronically tumor necrosis factor alpha and interleukin 6 release by uraemic monocytes. Nephrol Dial Transplant 1995;10:328–333.
58.
Buoncristiani U, Galli F, Rodivati S, Albertini MC, Campus G, Canestrari F: Oxidative damage during hemodialysis using a vitamin-E-modified dialysis membrane: A preliminary characterization. Nephron 1997;77:57–61.
59.
Machlin LJ: Use and safety of elevated dosages of vitamin E in adults. Int J Vitamin Nutr Res Suppl 1989;30:56–58.
60.
Tielemans CL, Delville JPC, Husson CP, Madhoun P, Lambrechts AM, Goldman M, Vanherweghem JL: Adhesion molecules and leukocytes common antigen on monocytes and granulocytes during hemodialysis. Clin Nephrol 1993;39:158–165.
61.
Brancaccio D, Bellotti U, Lasi B, Padovese P, Cozzolino M, Carpani P, Mangione P, Giorgetti S, Gallieni M: Effects of a vitamin E-modified dialyzer on beta-2-microglobulin structure and removal. Contrib Nephrol. Basel, Karger, 1999, vol 127, pp 147–155.
62.
Bonnefont-Rousselot D, Lehamann E, Jaudon MC, Delatore J, Perrone B, Reehke JP: Blood oxidative stress and lipoprotein oxidizability in hemodialysis patients: Effect of the use of a vitamin E-coated dialysis membrane. Nephrol Dial Transplant 2000;15:2020–2028.
63.
Miyazaki H, Matsuoka H, et al: Hemodialysis impairs endothelial function via oxidative stress: Effects of vitamin E-coated dialyzer. Circulation 2000;101:1002–1006.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the...
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.